NASDAQ · PGEN

Precigen, Inc.

Healthcare · Biotechnology

$6.68▼ 1.76% ($0.12)at close

After hours$6.60▼ 1.18%7:30 PM ET

52-week

$2.99$7.72

Market cap

What the market price implies · Reverse DCF

To support a price of $6.68, this model requires revenue to grow by 43.54%/yr over the next 10 years, compounded annually.

Historical revenue grew by -9.23%/yr over the past 4 years. The required annual growth rate is 52.77 percentage points higher.

Selected forecast · Base scenario

19.61%/yr · actual 10-year annualized revenue growth

Year 1 growth: 40%

Market-implied · Base operating assumptions + edited margins

43.54%/yr · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Revenue & margin DCF

Price used

$6.68

Estimated value / share

$0.82

Base scenario

This estimate is 87.69% below the price used.

USD · TTM ending 2026-06-30

Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.

Year 1 growth 40% · Ending margin 0% · Discount rate 10.46%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 10, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 11, 2026, 1:13 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Optimism is getting priced inModerate confidence

1Y Price: 63.73%Revenue (TTM): 1,875.05%FCF (TTM): -66%P/S: 73rd pct

What changed

The stock rose 63.73% over the last year. Revenue grew 1,875.05% over the trailing twelve months. Operating margin moved from -2,399.49% to -46.08%. Free cash flow declined 66% over the trailing twelve months.

What the market seems to be pricing

The stock is trading toward the richer end of its historical P/S range (73rd percentile) while business metrics are improving. More of the upside is already embedded in the multiple now.

What would invalidate this read

Operating margin is at -46.08% — continued expansion would be needed to justify the premium. Revenue growth of 1,875.05% is encouraging, but any deceleration puts the stretched multiple at risk. This read changes if revenue, margins, and cash flow continue to improve faster than expected — in that case the richer multiple could still prove conservative.

Performance

Return analysis

Company profile

Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies.

CEOHelen Sabzevari

SectorHealthcare

IndustryBiotechnology

Employees160

IPO dateAug 8, 2013

https://www.precigen.com

Market multiples

Forward P/E—

EV/EBITDA-5.51

Enterprise value$1.34B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth6,322.66%

Gross margin89.56%▲45.8ppvs FY2024

Operating margin-46.08%▲2339.4ppvs FY2024

ROEN/A

Analyst consensus

RatingBuy

Target price$18.00▲169.46%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 12, 2026

Q4 FY26 · EPS est $0.09 · Revenue est $69.21M

View